{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:49:52Z","timestamp":1790693392526,"version":"4.1.0"},"reference-count":41,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.3892\/mco.2016.957","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T19:50:48Z","timestamp":1503517848000},"page":"300-306","source":"Crossref","is-referenced-by-count":24,"title":["Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences"],"prefix":"10.3892","volume":"5","author":[{"given":"Mohamed","family":"Badr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehad","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Abdel","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Shahbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahbaa","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"key20180107150127_b1-mco-0-0-957","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2008.12.009","article-title":"Risk assessment in fever and neutropenia in children with cancer: What did we learn?","volume":"72","author":"te Poele","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107150127_b2-mco-0-0-957","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180107150127_b3-mco-0-0-957","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: Risks, consequences and new direction for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"key20180107150127_b4-mco-0-0-957","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/1078155213492450","article-title":"Incidence, treatment and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings","volume":"20","author":"Weycker","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"key20180107150127_b5-mco-0-0-957","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hon.2040","article-title":"Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department","volume":"31","author":"Lynn","year":"2013","journal-title":"Hematol Oncol"},{"key":"key20180107150127_b6-mco-0-0-957","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","volume":"16","author":"Dulisse","year":"2013","journal-title":"J Med Econ"},{"key":"key20180107150127_b7-mco-0-0-957","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key20180107150127_b8-mco-0-0-957","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bjhh.2014.11.012","article-title":"Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay","volume":"37","author":"Boada","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"key20180107150127_b9-mco-0-0-957","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2165\/11593060-000000000-00000","article-title":"Acute myeloid leukaemia: Optimal management and recent developments","volume":"71","author":"Villela","year":"2011","journal-title":"Drugs"},{"key":"key20180107150127_b10-mco-0-0-957","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer"},{"key":"key20180107150127_b11-mco-0-0-957","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107150127_b12-mco-0-0-957","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20180107150127_b13-mco-0-0-957","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","article-title":"The economics of febrile neutropenia: Implications for the use of colony-stimulating factors","volume":"34","author":"Lyman","year":"1998","journal-title":"Eur J Cancer"},{"key":"key20180107150127_b14-mco-0-0-957","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal and prostate cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"key20180107150127_b15-mco-0-0-957","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10156-011-0283-5","article-title":"Identifying risk factors for refractory febrile neutropenia in patients with lung cancer","volume":"18","author":"Fujita","year":"2012","journal-title":"J Infect Chemother"},{"key":"key20180107150127_b16-mco-0-0-957","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s101560170027","article-title":"Management of fever in neutropenic patients","volume":"7","author":"Bodey","year":"2001","journal-title":"J Infect Chemother"},{"key":"key20180107150127_b17-mco-0-0-957","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key20180107150127_b18-mco-0-0-957","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10156-012-0478-4","article-title":"Risk factors for refractory febrile neutropenia in urological chemotherapy","volume":"19","author":"Yasufuku","year":"2013","journal-title":"J Infect Chemo"},{"key":"key20180107150127_b19-mco-0-0-957","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: A practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"key20180107150127_b20-mco-0-0-957","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P","article-title":"The predictive value of body protein for chemotherapy-induced toxicity","volume":"88","author":"Aslani","year":"2000","journal-title":"Cancer"},{"key":"key20180107150127_b21-mco-0-0-957","first-page":"21","article-title":"Chemotherapy induced neutropenia: Important new data to guide nursing assessment and management","volume":"4","author":"Christopher","year":"2006","journal-title":"Adv Stud Nurs"},{"key":"key20180107150127_b22-mco-0-0-957","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1081\/CNV-46402","article-title":"Environmental and genetic risk factors for childhood leukemia: Appraising the evidence","volume":"23","author":"Buffler","year":"2005","journal-title":"Cancer Invest"},{"key":"key20180107150127_b23-mco-0-0-957","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00062752-200205000-00006","article-title":"Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients","volume":"9","author":"Lyman","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"key20180107150127_b24-mco-0-0-957","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","article-title":"Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis","volume":"16","author":"Gomez","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180107150127_b25-mco-0-0-957","first-page":"431a","article-title":"First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL) patients on standard-dose CHOP therapy","volume":"98","author":"Caggiano","year":"2001","journal-title":"Blood"},{"key":"key20180107150127_b26-mco-0-0-957","first-page":"255b","article-title":"Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy","volume":"21","author":"Meza","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key20180107150127_b27-mco-0-0-957","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1078155201jp084oa","article-title":"Predictors for chemotherapy-related severe or febrile neutropenia: A review of the clinical literature","volume":"7","author":"Wilson-Royalty","year":"2002","journal-title":"J Oncol Pharm Pract"},{"key":"key20180107150127_b28-mco-0-0-957","first-page":"942","article-title":"Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia","volume":"56","author":"Ghalaut","year":"2008","journal-title":"J Assoc physician India"},{"key":"key20180107150127_b29-mco-0-0-957","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double blind, placebo-controlled phase III study of filgrastim in remission induction and consideration therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"key":"key20180107150127_b30-mco-0-0-957","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia. CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"key":"key20180107150127_b31-mco-0-0-957","first-page":"237","article-title":"Bacterial infections in pediatric patients with chemotherapy induced neutropenia","volume":"54","author":"Mahmud","year":"2004","journal-title":"JPMA"},{"key":"key20180107150127_b32-mco-0-0-957","first-page":"115","article-title":"Febrile neutropenia: A retrospective study in Srinagarind Hospital","volume":"15","author":"Anunnatsiri","year":"1998","journal-title":"J infect Dis Antimicrob agents"},{"key":"key20180107150127_b33-mco-0-0-957","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.22484","article-title":"Updated clinical practice guidelines for the prevention and treatment of mucositis","volume":"109","author":"Keefe","year":"2007","journal-title":"Cancer"},{"key":"key20180107150127_b34-mco-0-0-957","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"key20180107150127_b35-mco-0-0-957","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.critrevonc.2009.03.004","article-title":"Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey","volume":"72","author":"Repetto","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107150127_b36-mco-0-0-957","first-page":"11","article-title":"The timing of chemotherapy-induced neutropenia and its clinical and economic impact","volume":"20","author":"Ozer","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"key20180107150127_b37-mco-0-0-957","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741\/cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107150127_b38-mco-0-0-957","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"key20180107150127_b39-mco-0-0-957","first-page":"250a","article-title":"Cost and mortality associated with febrile neutropenia in adult cancer patients","volume":"21","author":"Kuderer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key20180107150127_b40-mco-0-0-957","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1592\/phco.21.7.684.34568","article-title":"Economic impact of neutropenia and febrile neutropenia in breast cancer: Estimates from two national databases","volume":"21","author":"Gandhi","year":"2001","journal-title":"Pharmacotherapy"},{"key":"key20180107150127_b41-mco-0-0-957","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","article-title":"Cost of neutropenic complications of chemotherapy","volume":"19","author":"Weycker","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T03:49:59Z","timestamp":1602820199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2016.957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,7,12]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.3892\/mco.2016.957"],"URL":"https:\/\/doi.org\/10.3892\/mco.2016.957","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]}}}